- Home
- SOGP vs BOLD Comparison
SOGP vs BOLD Comparison
Compare SOGP & BOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SOGP
- BOLD
- Stock Information
- Founded
- SOGP 2010
- BOLD 2018
- Country
- SOGP Singapore
- BOLD United States
- Employees
- SOGP N/A
- BOLD N/A
- Industry
- SOGP
- BOLD
- Sector
- SOGP
- BOLD
- Exchange
- SOGP NYSE
- BOLD Nasdaq
- Market Cap
- SOGP 29.5M
- BOLD 24.4M
- IPO Year
- SOGP 2020
- BOLD 2024
- Fundamental
- Price
- SOGP $5.14
- BOLD $1.27
- Analyst Decision
- SOGP
- BOLD Buy
- Analyst Count
- SOGP 0
- BOLD 3
- Target Price
- SOGP N/A
- BOLD $4.00
- AVG Volume (30 Days)
- SOGP 151.4K
- BOLD 200.8K
- Earning Date
- SOGP 08-05-2025
- BOLD 08-11-2025
- Dividend Yield
- SOGP N/A
- BOLD N/A
- EPS Growth
- SOGP N/A
- BOLD N/A
- EPS
- SOGP N/A
- BOLD N/A
- Revenue
- SOGP $278,363,908.00
- BOLD N/A
- Revenue This Year
- SOGP $48.88
- BOLD N/A
- Revenue Next Year
- SOGP N/A
- BOLD N/A
- P/E Ratio
- SOGP N/A
- BOLD N/A
- Revenue Growth
- SOGP N/A
- BOLD N/A
- 52 Week Low
- SOGP $1.18
- BOLD $1.00
- 52 Week High
- SOGP $6.89
- BOLD $4.72
- Technical
- Relative Strength Index (RSI)
- SOGP 53.35
- BOLD N/A
- Support Level
- SOGP $5.03
- BOLD N/A
- Resistance Level
- SOGP $5.86
- BOLD N/A
- Average True Range (ATR)
- SOGP 0.85
- BOLD 0.00
- MACD
- SOGP -0.19
- BOLD 0.00
- Stochastic Oscillator
- SOGP 44.27
- BOLD 0.00
About SOGP SOUND GROUP INC SPON ADS EA REP 200 ORD SHS(POST SPLIT)
Sound Group Inc is a world-wide audio-centric social and entertainment company. It Leverages broad product portfolio and in-house technologies, Sound Group caters to user interest in audio entertainment and social networking. Sound Group nurtures a globally diverse and inclusive team, drawing on talent from various countries and regions world-wide.
About BOLD Boundless Bio Inc. Common Stock
Boundless Bio Inc is a clinical-stage oncology company. The company is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Its ecDTx, BBI-355, is a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells.